Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan C Buckner

Showing results (41-50 of 138) with videos related to

Pageof 14
Sort By:
Mayo Clinic Proceedings|October 3, 2007
Central nervous system tumorsJan C Buckner, Paul D Brown, Brian P O'Neill, et al.
Investigational New Drugs|May 6, 2009
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancerJan C Buckner, Bahram Forouzesh, Charles Erlichman, et al.
Pediatric Blood & Cancer|July 12, 2017
Optimal radiotherapy target volumes in intracranial nongerminomatous germ cell tumors: Long-term institutional experience with chemotherapy, surgery, and dose- and field-adapted radiotherapyWilliam G Breen, Miran J Blanchard, Amulya Nageswara Rao, et al.
International Journal of Radiation Oncology, Biology, Physics|January 5, 2010
Long-term follow-up of dose-adapted and reduced-field radiotherapy with or without chemotherapy for central nervous system germinomaAshley W Jensen, Nadia N Issa Laack, Jan C Buckner, et al.
Neuro-Oncology|May 12, 2011
Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytomaDerek R Johnson, David W Kimmel, Patrick A Burch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigationShauna L Hillman, Ming-Wen An, Michael J O'Connell, et al.
Journal of Neurosurgery|June 21, 2003
Hemangiopericytoma in the central nervous system: treatment, pathological features, and long-term follow up in 38 patientsRobert D Ecker, W Richard Marsh, Bruce E Pollock, et al.
Neuro-Oncology|October 11, 2005
GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trialsSusan M Chang, Sharon L Reynolds, Nicholas Butowski, et al.
Cancer|April 23, 2008
Malignant primary cardiac tumors: review of a single institution experienceLijo Simpson, Shaji K Kumar, Scott H Okuno, et al.
Neuro-Oncology|November 17, 2006
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiformeKarla V Ballman, Jan C Buckner, Paul D Brown, et al.
Pageof 14

Showing results (41-50 of 138) with videos related to

Sort By:
Pageof 14
Mayo Clinic Proceedings|October 3, 2007
Central nervous system tumorsJan C Buckner, Paul D Brown, Brian P O'Neill, et al.
Investigational New Drugs|May 6, 2009
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancerJan C Buckner, Bahram Forouzesh, Charles Erlichman, et al.
Pediatric Blood & Cancer|July 12, 2017
Optimal radiotherapy target volumes in intracranial nongerminomatous germ cell tumors: Long-term institutional experience with chemotherapy, surgery, and dose- and field-adapted radiotherapyWilliam G Breen, Miran J Blanchard, Amulya Nageswara Rao, et al.
International Journal of Radiation Oncology, Biology, Physics|January 5, 2010
Long-term follow-up of dose-adapted and reduced-field radiotherapy with or without chemotherapy for central nervous system germinomaAshley W Jensen, Nadia N Issa Laack, Jan C Buckner, et al.
Neuro-Oncology|May 12, 2011
Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytomaDerek R Johnson, David W Kimmel, Patrick A Burch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigationShauna L Hillman, Ming-Wen An, Michael J O'Connell, et al.
Journal of Neurosurgery|June 21, 2003
Hemangiopericytoma in the central nervous system: treatment, pathological features, and long-term follow up in 38 patientsRobert D Ecker, W Richard Marsh, Bruce E Pollock, et al.
Neuro-Oncology|October 11, 2005
GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trialsSusan M Chang, Sharon L Reynolds, Nicholas Butowski, et al.
Cancer|April 23, 2008
Malignant primary cardiac tumors: review of a single institution experienceLijo Simpson, Shaji K Kumar, Scott H Okuno, et al.
Neuro-Oncology|November 17, 2006
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiformeKarla V Ballman, Jan C Buckner, Paul D Brown, et al.
Pageof 14